ReviewF1000Research2016
Emerging concepts for PI3K/mTOR inhibition as a potential treatment for osteosarcoma.
Review in F1000Research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 27 citations in OpenAlex.
- Drug Sensitivity Testing in Osteosarcoma: A Case Report.Current oncology (Toronto, Ont.) · 2025Article
- Targeting the mitochondrial protein YME1L to inhibit osteosarcoma cell growth in vitro and in vivo.Cell death & disease · 2024Article
- Evaluation of the Biological Effect of Non-UV-Activated Bergapten on Selected Human Tumor Cells and the Insight into the Molecular Mechanism of Its Action.International journal of molecular sciences · 2023Article
- HOXC13-driven TIMM13 overexpression promotes osteosarcoma cell growth.Cell death & disease · 2023Article
- ADCK1 is a potential therapeutic target of osteosarcoma.Cell death & disease · 2022Article
- Design and development of novel 1,2,3-triazole chalcone derivatives as potential anti-osteosarcoma agentsActa pharmaceutica (Zagreb, Croatia) · 2022Article
- 1,3,5-triazines inhibit osteosarcoma and avert lung metastasis in a patient-derived orthotopic xenograft mouse model with favorable pharmacokinetics.Iranian journal of basic medical sciences · 2022Article
- A Multi-Objective Approach for Anti-Osteosarcoma Cancer Agents Discovery through Drug Repurposing.Pharmaceuticals (Basel, Switzerland) · 2020Article
- Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies.International journal of molecular sciences · 2020Review
- Role of TKI for Metastatic Osteogenic Sarcoma.Current treatment options in oncology · 2020Review
- CDKL3 promotes osteosarcoma progression by activating Akt/PKB.Life science alliance · 2020Article
- [Osteoid-forming bone tumors : Morphology and current translational cell biology].Der Pathologe · 2020Review
- Genome-Informed Targeted Therapy for Osteosarcoma.Cancer discovery · 2019Article
- Identification of a Two-Gene (Frontiers in oncology · 2019Article
- DOX-Vit D, a Novel Doxorubicin Delivery Approach, Inhibits Human Osteosarcoma Cell Proliferation by Inducing Apoptosis While Inhibiting Akt and mTOR Signaling Pathways.Pharmaceutics · 2018Article
- Effect and Mechanism ofBalkan medical journal · 2018Article
- ERK inhibition sensitizes CZ415-induced anti-osteosarcoma activityOncotarget · 2017Article
- Assessment of GSK1904529A as a promising anti-osteosarcoma agent.Oncotarget · 2017Article
- Advances in the Treatment of Pediatric Bone Sarcomas.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2017Review
- Advances in the management of osteosarcoma.F1000Research · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Patients with metastatic and recurrent osteosarcoma fare poorly, and new therapeutic strategies are needed to improve survival. Several recent complementary genomic and pathway analyses of both murine and human osteosarcoma have revealed common aberrations of the phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway in osteosarcoma. Preclinical data demonstrate that inhibition of PI3K and mTOR with either a combination of single agents or dual inhibiting compounds can decrease cell proliferation and induce cell cycle arrest and apoptosis. With a lack of available clinical agents active in osteosarcoma, PI3K/mTOR inhibition represents a potential vulnerability in osteosarcoma that warrants clinical investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.